Top 10 Chinese Exporters of Finished Pharmaceutical Products (2025 Compiled by Dengyue Pharmaceuticals)
As we step into the latter half of 2025, China's pharmaceutical industry continues to assert its dominance on the global stage. With total pharmaceutical exports reaching new heights amid recovering global supply chains, Chinese companies are leading in the production and export of finished pharmaceutical products, including generics, vaccines, and innovative therapies. According to recent trade data, China's pharma exports grew by approximately 8% year-over-year, driven by demand from markets like the United States, Europe, and Southeast Asia. This growth underscores the sector's resilience despite regulatory challenges and geopolitical tensions.
Compiled and edited by DengYue Medicine, a Hong Kong-based wholesaler specializing in the import and export of new, specialty, and rare drugs since 2019, this blog post highlights the top 10 Chinese exporters of finished pharmaceutical products for 2025. Our ranking is based on a synthesis of sales value, export volumes, market presence, and data from sources like Statista, industry reports, and the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCMHPIE). Note that while exact export figures for finished products can vary, these companies are recognized for their significant international shipments of ready-to-use drugs.
Key Trends in 2025
Before diving into the list, let's note a few trends shaping the industry:
- Focus on Innovation: Companies are investing heavily in R&D, with oncology and biologics leading export growth.
- Global Compliance: Many have achieved US FDA and EU approvals, facilitating exports to regulated markets.
- Supply Chain Shifts: Post-pandemic, there's increased emphasis on diversified exports to emerging markets like ASEAN and Latin America.
- Challenges: Stricter international regulations and domestic policy changes continue to influence rankings.
Top 10 Exporters
| Rank | Company Name | Key Details |
|---|---|---|
| 1 | Shanghai Pharmaceuticals | Leading with approximately $38 billion in sales, focusing on distribution and exports of generics and finished drugs to over 100 countries. |
| 2 | Sinopharm Group | State-owned giant with revenues exceeding $40 billion; major exporter of vaccines and essential medicines, particularly to developing nations. |
| 3 | CSPC Pharmaceutical Group | Tops mid-2025 revenue rankings at around $130 billion (group level); strong in antibiotics and oncology exports. |
| 4 | Jiangsu Hengrui Pharmaceuticals | Global rank #43 with $3.89 billion revenue; excels in oncology finished products exported to Europe and the US. |
| 5 | Fosun Pharma | Includes Guilin Pharma, a perennial top exporter; $90 billion revenue, with focus on antimalarials and generics for Africa and Asia. |
| 6 | Qilu Pharmaceutical | Over 300 products, including generics and biosimilars; significant exports to global markets, emphasizing quality and affordability. |
| 7 | Zhejiang Huahai Pharmaceutical | Historical leader in API and finished products; continues strong exports of cardiovascular drugs to the US and EU. |
| 8 | Livzon Pharmaceutical Group | Zhuhai-based with focus on reproductive health and biologics; active exporter to Southeast Asia and beyond. |
| 9 | Sino Biopharmaceutical | Global rank #42 with $4.02 billion; exports innovative drugs in cardio and oncology segments. |
| 10 | Hong Kong DengYue Medicine Limited | Hong Kong-based wholesaler founded in 2019, specializing in the import and export of new, specialty, and rare drugs for chronic and oncological diseases, with growing international shipments. |
These companies represent the backbone of China's finished pharma exports, contributing to global healthcare access. For instance, Sinopharm's vaccine exports have been pivotal in international aid efforts, while Hengrui's oncology drugs are gaining traction in Western markets.
Outlook for the Rest of 2025
Looking ahead, we at DengYue Medicine anticipate further growth in biopharma exports, with companies like WuXi AppTec and Innovent potentially climbing ranks through CDMO services and innovative pipelines. However, navigating US-China trade dynamics and enhancing quality standards will be crucial.
If you're interested in partnering for imports or exports of specialty drugs, contact DengYue Medicine at our Hong Kong office. Stay tuned for more insights!
Compiled by DengYue Medicine Research Team, October 2025.
Turkish
English
Arabic
French
Spanish
Portuguese
Deutsch
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
